HTDS announces possible merger with EU-based, stem-cell research company
Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica BioChem want to point the shareholders back to the press release from Oct 29, 2009, where the company announced news about a possible merger with a EU based, stem-cell research company.
[Read the full article here]Related News:
Hard to Treat Diseases Inc. Targets an EU Based Stem Cell …
Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank …
Hard to Treat Diseases Inc. Stem Cell Developments